NDC product
Guaifenesin
NDC 68001-561 · BluePoint Laboratories
Key facts
| Product NDC | 68001-561 |
|---|---|
| Proprietary name | Guaifenesin |
| Nonproprietary name | Guaifenesin |
| Substances | GUAIFENESIN |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | BluePoint Laboratories |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA210453 |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE] |
| Marketing start | Mar 15, 2023 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: